Navigation Links
HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
Date:4/8/2008

COLORADO SPRINGS, Colo., April 8, 2008 /PRNewswire/ -- HemoGenix(R), Inc., a privately-held contract research and assay development company, reported that the USPTO has issued the first two of several patent applications for the company's HALO(R) technology. HALO(R) is the 21st century answer and the only alternative to, and replacement for, the traditional colony-forming cell (CFC) assay, first described in 1966.

HALO(R) was developed and validated by HemoGenix(R) with the help of a SBIR Phase I and II grant from the National Cancer Institute (NCI). Development began in January 2001. The HALO(R) Platform for in vitro hemotoxicity testing of new drug candidates being developed by biotechnology and pharmaceutical companies was launched at the Society of Toxicology meeting in March 2001. Since that time, HemoGenix(R) has developed 3 versions of its HALO(R) Platform, each designed for specific applications.

The HALO(R) Research Platform is for basic research scientists in academia and other research institutions. The HALO(R) Stem and Progenitor Cell -- Quality Control (SPC-QC) and HALO(R)-96 PQR (Potency, Quality Release) Platforms were designed for stem cell transplantation and cord blood bank processing laboratories to address the requirement for "appropriate" and "validated" assays for umbilical cord blood stem cell products prior to transplantation into patients. Finally, the HALO(R) Predictive Hemotoxicity Platform was designed for all stages of drug development from early high-throughput screening to pre-clinical studies and patient monitoring during clinical trials. The HALO(R) Hemotoxicity Platform provides easy to use, robust, reliable and validated predictive tools to detect potential toxic side effects to stem cells of the blood-forming (hematopoietic) system for drug development and environmental agent testing.

All HALO(R) platforms rely on highly sensitive and fully standardized, instrument-based, ATP bioluminescence technology. This innovative technology has allowed HemoGenix(R) to become "The Leader in Hemotoxicity Testing."

Instrumental in the issuance of the patents by the USPTO were David Rosenbaum and Donna Becker of Rosenbaum & Associates, P.C. of Northbrook, IL. "If it was not for David's interest and belief in HemoGenix and Donna's exuberance in learning and obtaining a thorough understanding of our work and products and her persistence and communication with the USPTO, we would certainly not be in this position today," said Ivan Rich, Ph.D., Founder and CEO of HemoGenix(R). "For a small, but growing company like HemoGenix(R), IP is of fundamental importance to us, not only as validation for what we do, but also for future business, market share and strategic partnerships. This is an important milestone for us. I am extremely grateful to David Rosenbaum and Donna Becker for all the help, assistance and trust they have given us and continue to give us."

About HemoGenix(R), Inc.

HemoGenix(R) Inc., a privately-held contract research and assay development company was started in 2000 in South Carolina and relocated to Colorado Springs, Colorado in 2003. HemoGenix has developed its own portfolio of proprietary and now patented in vitro assay platforms for basic research, stem cell quality control, potency and release assays for stem cell transplantation processing laboratories and toxicity, safety and risk assessment for drug development and environmental testing. HemoGenix(R) develops and validates its in vitro assays first for its contract services and then as assay kits for in house use that are sold directly or through its distributors worldwide.

About Rosenbaum & Associates, P.C.

Rosenbaum & Associates, P.C., located in Northbrook, IL, is a full spectrum intellectual property law firm providing services for the life sciences community. The firm specializes in meeting the needs of start-up and emerging companies and has successfully worked with individual inventors, university faculty members and entrepreneurs during the entire corporate life-cycle. The firm is committed to providing business-oriented intellectual property legal services in a prompt, courteous and professional manner.

CONTACT:

Ivan N. Rich, Ph.D.

Founder & CEO

719-264-6250


'/>"/>
SOURCE HemoGenix(R), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
2. SemBioSys receives milestone payments from AVAC Ltd.
3. Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative
4. EntreMed Receives Nasdaq Deficiency Notice
5. Memory Pharmaceuticals Receives Nasdaq Notification
6. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Pharmasset Receives $10 Million of Working Capital
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):